A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorEli Lilly and Company
About this trial
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
Eligibility criteria
Qualifiers
Have type 2 diabetes
Are on stable treatment for type 2 diabetes for at least 90 days prior to screening
Have a BMI ≥ 27 kg/m2
Have a stable body weight (<5% body weight change) for 90 days prior to screening
Disqualifiers
Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
Have type 1 diabetes
amylin analogs
Trial design
Treatments tested in this trial
- Eloralintide
- Placebo
Treatment groups
1,035 Participants
are divided into 5 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov